BRAFTOVI regimen showed a 51% reduced risk of death vs. standard chemo (HR 0.49). Median survival with BRAFTOVI combo reached 30.3 months vs. 15.1 months for chemo. Rebound or breakdown? See how ...

Pfizer Inc. (NYSE:PFE) on Friday released data from Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil ...

A 58-year-old U.S. woman has succumbed to iatrogenic Creutzfeldt-Jakob disease (iCJD)—a lethal neurodegenerative and incurable brain disorder—almost 50 years after she was treated with cadaver ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

ePHOTOzine brings you a daily round up of all the latest photography news including camera news, exhibitions, events, special offers, industry news, digital photography news, announcements and ...

In this section you'll find photographic features that explore holidays and photography courses, details about members meetings, trials and tribulations of installing new software along with ...

Um Unternehmen dabei zu unterstützen, den immer strengeren Datenschutzbestimmungen einen Schritt voraus zu sein, hat Regula, ein globaler Entwickler von Identitätsprüfungslösungen, seine ...

Between 1970 and 1980 19 patients aged 13 months to 47 years (mean 16 years) had surgical repair of lesions associated with corrected transposition. Four had had previous palliative surgery.